{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:21:31Z","timestamp":1794262891461,"version":"4.9.0"},"reference-count":131,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K08-NS128266-02"],"award-info":[{"award-number":["K08-NS128266-02"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["2004757180"],"award-info":[{"award-number":["2004757180"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neurofibromatosis Therapeutic Acceleration Program","award":["K08-NS128266-02"],"award-info":[{"award-number":["K08-NS128266-02"]}]},{"name":"Neurofibromatosis Therapeutic Acceleration Program","award":["2004757180"],"award-info":[{"award-number":["2004757180"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Neurofibromatosis type 1 (NF1) is a common genetic disorder resulting in the development of both benign and malignant tumors of the peripheral nervous system. NF1 is caused by germline pathogenic variants or deletions of the NF1 tumor suppressor gene, which encodes the protein neurofibromin that functions as negative regulator of p21 RAS. Loss of NF1 heterozygosity in Schwann cells (SCs), the cells of origin for these nerve sheath-derived tumors, leads to the formation of plexiform neurofibromas (PNF)\u2014benign yet complex neoplasms involving multiple nerve fascicles and comprised of a myriad of infiltrating stromal and immune cells. PNF development and progression are shaped by dynamic interactions between SCs and immune cells, including mast cells, macrophages, and T cells. In this review, we explore the current state of the field and critical knowledge gaps regarding the role of NF1(Nf1) haploinsufficiency on immune cell function, as well as the putative impact of Schwann cell lineage states on immune cell recruitment and function within the tumor field. Furthermore, we review emerging evidence suggesting a dueling role of Nf1+\/- immune cells along the neurofibroma to MPNST continuum, on one hand propitiating PNF initiation, while on the other, potentially impeding the malignant transformation of plexiform and atypical neurofibroma precursor lesions. Finally, we underscore the potential implications of these discoveries and advocate for further research directed at illuminating the contributions of various immune cells subsets in discrete stages of tumor initiation, progression, and malignant transformation to facilitate the discovery and translation of innovative diagnostic and therapeutic approaches to transform risk-adapted care.<\/jats:p>","DOI":"10.3390\/cancers16050994","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T08:13:44Z","timestamp":1709194424000},"page":"994","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The NF1+\/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation"],"prefix":"10.3390","volume":"16","author":[{"given":"Emily E.","family":"White","sequence":"first","affiliation":[{"name":"Medical Scientist Training Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"Division of Pediatric Hematology\/Oncology\/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","article-title":"The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins","volume":"63","author":"Ballester","year":"1990","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","article-title":"The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21","volume":"63","author":"Martin","year":"1990","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","article-title":"The neurofibromatosis type 1 gene encodes a protein related to GAP","volume":"62","author":"Xu","year":"1990","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: Impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ng0996-110","article-title":"Identification of NF1 mutations in both alleles of a dermal neurofibroma","volume":"14","author":"Sawada","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1086\/515504","article-title":"Confirmation of a double-hit model for the NF1 gene in benign neurofibromas","volume":"61","author":"Serra","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K","article-title":"Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma","volume":"24","author":"Kluwe","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ng0293-122","article-title":"Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis","volume":"3","author":"Legius","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1159\/000526844","article-title":"Atypical Neurofibromatous Neoplasm with Uncertain Biologic Potential in the Posterior Mediastinum of a Young Patient with Neurofibromatosis Type 1: A Case Report","volume":"15","author":"Miyamoto","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/neuonc\/noz028","article-title":"Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas","volume":"21","author":"Pemov","year":"2019","journal-title":"Neuro-Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/hmg\/ddz095","article-title":"Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation","volume":"28","author":"Rhodes","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-19-1429","article-title":"Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST","volume":"80","author":"Chaney","year":"2020","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"Beert","year":"2014","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14992","DOI":"10.1038\/s41598-017-15183-1","article-title":"The genomic landscape of malignant peripheral nerve sheath tumors: Diverse drivers of Ras pathway activation","volume":"7","author":"Brohl","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","article-title":"Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA","volume":"13","author":"Steele","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"Higham","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1074\/jbc.M009202200","article-title":"Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-\/- cells","volume":"276","author":"Hiatt","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1158\/1078-0432.CCR-03-0769","article-title":"Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1","volume":"10","author":"Mashour","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccell.2014.09.009","article-title":"Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma","volume":"26","author":"Chen","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1038\/s41388-021-01979-z","article-title":"Tumorigenesis in neurofibromatosis type 1: Role of the microenvironment","volume":"40","author":"Jiang","year":"2021","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type 1","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1101\/gad.8.9.1019","article-title":"Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues","volume":"8","author":"Brannan","year":"1994","journal-title":"Genes Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.1068452","article-title":"Neurofibromas in NF1: Schwann cell origin and role of tumor environment","volume":"296","author":"Zhu","year":"2002","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","article-title":"Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells","volume":"13","author":"Wu","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2008.01.002","article-title":"Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation","volume":"13","author":"Zheng","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/0008-5472.CAN-10-4558","article-title":"Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation","volume":"71","author":"Mayes","year":"2011","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1158\/1535-7163.MCT-19-0123","article-title":"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice","volume":"18","author":"Burks","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1158\/0008-5472.CAN-10-4577","article-title":"Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development","volume":"71","author":"Le","year":"2011","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2008.01.003","article-title":"The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells","volume":"13","author":"Joseph","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.stem.2009.03.017","article-title":"Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas","volume":"4","author":"Le","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e139807","DOI":"10.1172\/JCI139807","article-title":"Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins","volume":"131","author":"Mo","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","article-title":"Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma","volume":"59","author":"Lau","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)81764-X","article-title":"Ras promotes cell survival in Drosophila by downregulating hid expression","volume":"95","author":"Kurada","year":"1998","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1096\/fasebj.9.9.7601337","article-title":"The MAPK signaling cascade","volume":"9","author":"Seger","year":"1995","journal-title":"FASEB J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions","volume":"24","author":"Yoon","year":"2006","journal-title":"Growth Factors"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1158\/1078-0432.CCR-22-2854","article-title":"Combined CDK4\/6 and ERK1\/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma","volume":"29","author":"Flint","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"i129","DOI":"10.1093\/neuonc\/noac079.472","article-title":"NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"24","author":"Kiaei","year":"2022","journal-title":"Neuro-Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"iii420","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"Nfb-17. mek inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: A report from pnoc and the nf clinical trials consortium","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro-Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA Approval Summary: Selumetinib for Plexiform Neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Watson","year":"2014","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis Clinical Trials Consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1172\/JCI19195","article-title":"Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+\/- mast cells","volume":"112","author":"Yang","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","article-title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","volume":"125","author":"Prada","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"i23","DOI":"10.1093\/noajnl\/vdz045","article-title":"After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation","volume":"2","author":"Fletcher","year":"2019","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.onc.1204026","article-title":"The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells","volume":"20","author":"Mashour","year":"2001","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e154513","DOI":"10.1172\/jci.insight.154513","article-title":"Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment","volume":"7","author":"Kershner","year":"2022","journal-title":"JCI Insight"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41420-023-01392-3","article-title":"Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration","volume":"9","author":"Ding","year":"2023","journal-title":"Cell Death Discovery"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-020-15770-3","article-title":"Midkine activation of CD8+ T cells establishes a neuron\u2013immune\u2013cancer axis responsible for low-grade glioma growth","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.1101468","article-title":"The Cytokine Midkine and Its Receptor RPTP\u03b6 Regulate B Cell Survival in a Pathway Induced by CD74","volume":"188","author":"Cohen","year":"2012","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1253\/circj.CJ-17-0043","article-title":"Midkine Promotes Atherosclerotic Plaque Formation Through Its Pro-Inflammatory, Angiogenic and Anti-Apoptotic Functions in Apolipoprotein E-Knockout Mice","volume":"82","author":"Takemoto","year":"2018","journal-title":"Circ. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/glia.20776","article-title":"How does the Schwann cell lineage form tumors in NF1?","volume":"56","author":"Carroll","year":"2008","journal-title":"Glia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1469-7580.2002.00046.x","article-title":"Signals that determine Schwann cell identity","volume":"200","author":"Jessen","year":"2002","journal-title":"J. Anat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"203686","DOI":"10.1016\/j.cdev.2021.203686","article-title":"Schwann cell precursors: Where they come from and where they go","volume":"166","author":"Solovieva","year":"2021","journal-title":"Cells Dev."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Horner, S.J., Couturier, N., Gueiber, D.C., Hafner, M., and Rudolf, R. (2022). Development and In Vitro Differentiation of Schwann Cells. Cells, 11.","DOI":"10.3390\/cells11233753"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ge, L.L., Xing, M.Y., Zhang, H.B., and Wang, Z.C. (2022). Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage Development. Cancers, 14.","DOI":"10.3390\/cancers14184513"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1101\/gad.490608","article-title":"NF1 loss disrupts Schwann cell-axonal interactions: A novel role for semaphorin 4F","volume":"22","author":"Parrinello","year":"2008","journal-title":"Genes. Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.ejhg.5201676","article-title":"Neurofibromatosis 1","volume":"15","author":"Ferner","year":"2007","journal-title":"Eur. J. Human. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"i13","DOI":"10.1093\/noajnl\/vdz044","article-title":"New insights into the neurofibroma tumor cells of origin","volume":"2","author":"Li","year":"2019","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-18-0151","article-title":"Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","article-title":"Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells","volume":"9","author":"Radomska","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nn1299","article-title":"Neural crest boundary cap cells constitute a source of neuronal and glial cells of the PNS","volume":"7","author":"Maro","year":"2004","journal-title":"Nat. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cyto.2019.01.013","article-title":"The senescence-associated secretory phenotype and its regulation","volume":"117","author":"Rowell","year":"2019","journal-title":"Cytokine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Coppe","year":"2008","journal-title":"PLoS Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Homann, L., Rentschler, M., Brenner, E., Bohm, K., Rocken, M., and Wieder, T. (2022). IFN-gamma and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma. Cells, 11.","DOI":"10.3390\/cells11091514"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1073\/pnas.132080999","article-title":"Deciphering peripheral nerve myelination by using Schwann cell expression profiling","volume":"99","author":"Nagarajan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.neuron.2012.06.021","article-title":"c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration","volume":"75","author":"Latouche","year":"2012","journal-title":"Neuron"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fncel.2019.00033","article-title":"The Success and Failure of the Schwann Cell Response to Nerve Injury","volume":"13","author":"Jessen","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/glia.20766","article-title":"Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease","volume":"56","author":"Martini","year":"2008","journal-title":"Glia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0306-4522(98)00240-1","article-title":"Increased expression, axonal transport and release of pituitary adenylate cyclase-activating polypeptide in the cultured rat vagus nerve","volume":"88","author":"Reimer","year":"1999","journal-title":"Neuroscience"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuroscience.2007.09.084","article-title":"Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide","volume":"151","author":"Armstrong","year":"2008","journal-title":"Neuroscience"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.celrep.2013.08.033","article-title":"Injury signals cooperate with Nf1 loss to relieve the tumor-suppressive environment of adult peripheral nerve","volume":"5","author":"Ribeiro","year":"2013","journal-title":"Cell Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/-- and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1038\/s41467-018-07452-y","article-title":"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation","volume":"9","author":"Brosseau","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_88","first-page":"8573","article-title":"Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity","volume":"63","author":"Bajenaru","year":"2003","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jid.2023.01.043","article-title":"RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights","volume":"143","author":"Rhodes","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_90","first-page":"321","article-title":"The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis","volume":"144","author":"Iemura","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.191.1.181","article-title":"Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo","volume":"191","author":"Ingram","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1084\/jem.194.1.57","article-title":"Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro","volume":"194","author":"Ingram","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/hmg\/ddl165","article-title":"Nf1+\/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling","volume":"15","author":"Yang","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3892\/mmr.2017.6215","article-title":"Activation-induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation","volume":"15","author":"Xu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1038\/sj.onc.1210261","article-title":"Tumor microenvironment and neurofibromatosis type I: Connecting the GAPs","volume":"26","author":"Le","year":"2007","journal-title":"Oncogene"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.it.2004.02.013","article-title":"Mast cells: The Jekyll and Hyde of tumor growth","volume":"25","author":"Theoharides","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2008-04-155085","article-title":"Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+\/- mast cells","volume":"112","author":"McDaniel","year":"2008","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e28372","DOI":"10.1002\/pbc.28372","article-title":"Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1","volume":"67","author":"Armstrong","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","article-title":"A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching","volume":"129","author":"Riccardi","year":"1993","journal-title":"Arch. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1172\/JCI99424","article-title":"Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis","volume":"128","author":"Liao","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e168227","DOI":"10.1172\/JCI168227","article-title":"Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor","volume":"133","author":"Jiang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Boutilier, A.J., and Elsawa, S.F. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136995"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tins.2016.03.005","article-title":"Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System","volume":"39","author":"Chitu","year":"2016","journal-title":"Trends Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-016-1871-0","article-title":"Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients","volume":"65","author":"Farschtschi","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e98601","DOI":"10.1172\/jci.insight.98601","article-title":"Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice","volume":"4","author":"Fletcher","year":"2019","journal-title":"JCI Insight"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/NEN.0b013e318165eb75","article-title":"Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients","volume":"67","author":"Rodriguez","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.310797.117","article-title":"Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth","volume":"32","author":"Pan","year":"2018","journal-title":"Genes Dev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","article-title":"The molecular landscape of glioma in patients with Neurofibromatosis 1","volume":"25","author":"Ceccarelli","year":"2019","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum. Genom."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1158\/0008-5472.CAN-16-2643","article-title":"NF1(+\/-) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response","volume":"77","author":"Dodd","year":"2017","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"64300","DOI":"10.18632\/oncotarget.11734","article-title":"Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes","volume":"7","author":"Shurell","year":"2016","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"82037","DOI":"10.18632\/oncotarget.18301","article-title":"Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy","volume":"8","author":"Haworth","year":"2017","journal-title":"Oncotarget"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/humu.23552","article-title":"Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings","volume":"39","author":"Carrio","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Mitchell, D.K., Burgess, B., White, E., Smith, A.E., Sierra Potchanant, E.A., Mang, H., Rodriguez, B., Lu, Q., Qian, S., and Bessler, W. (2023). Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression. Clin. Cancer Res., OF1\u2013OF16.","DOI":"10.1158\/1078-0432.CCR-23-2548"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11060-023-04467-4","article-title":"Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy","volume":"164","author":"Bhandarkar","year":"2023","journal-title":"J. Neuro-Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-23-0749","article-title":"CDK4\/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression","volume":"29","author":"Kohlmeyer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CJI.0000000000000410","article-title":"Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks","volume":"45","author":"Larson","year":"2022","journal-title":"J. Immunother."},{"key":"ref_119","first-page":"182","article-title":"Complete Response to Pembrolizumab in a Patient with Malignant Peripheral Nerve Sheath Tumor: The First Case Reported","volume":"7","author":"Payandeh","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_120","first-page":"1","article-title":"Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274\/PD-L1 Amplification","volume":"3","author":"Bohanes","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/JCO.2022.40.16_suppl.9517","article-title":"Newly updated activity results of alrizomadlin (APG-115), a novel MDM2\/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors","volume":"40","author":"McKean","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1740925X04000274","article-title":"Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells","volume":"1","author":"Lee","year":"2004","journal-title":"Neuron Glia Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neulet.2005.12.027","article-title":"Immune system evasion by peripheral nerve sheath tumor","volume":"397","author":"Lee","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e153437","DOI":"10.1172\/JCI153437","article-title":"Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses","volume":"132","author":"Yan","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/modpathol.2016.45","article-title":"Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival","volume":"29","author":"Cleven","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-15-1090","article-title":"A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells","volume":"76","author":"Holzel","year":"2016","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/cam4.1977","article-title":"Prognostic significance of mast cell and microvascular densities in malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1","volume":"8","author":"Vasconcelos","year":"2019","journal-title":"Cancer Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"Dancsok","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","article-title":"Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs","volume":"20","author":"Patwardhan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-21-1779","article-title":"A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","volume":"27","author":"Manji","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"TPS11070","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS11070","article-title":"Phase 1\/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors","volume":"34","author":"Manji","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/994\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:55Z","timestamp":1760105215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":131,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16050994"],"URL":"https:\/\/doi.org\/10.3390\/cancers16050994","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}